These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 15546122)

  • 21. The design of clinical trials that evaluate antifungal prophylaxis and combination therapy: introduction and overview.
    Rex JH; Wingard JR; Wenzel R; Herbrecht R; Sobel J; Edwards JE
    Clin Infect Dis; 2004 Oct; 39 Suppl 4():S165-9. PubMed ID: 15546112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Animal models testing monotherapy versus combination antifungal therapy: lessons learned and future directions.
    Clemons KV; Stevens DA
    Curr Opin Infect Dis; 2006 Aug; 19(4):360-4. PubMed ID: 16804384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination antifungal therapy: what can and should we expect?
    Johnson MD; Perfect JR
    Bone Marrow Transplant; 2007 Aug; 40(4):297-306. PubMed ID: 17563740
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical efficacy of new antifungal agents.
    Kauffman CA
    Curr Opin Microbiol; 2006 Oct; 9(5):483-8. PubMed ID: 16904366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of systemic fungal infections: alternatives to itraconazole.
    Herbrecht R; Nivoix Y; Fohrer C; Natarajan-Amé S; Letscher-Bru V
    J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i39-i48. PubMed ID: 16120633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on echinocandin antifungals.
    Kauffman CA; Carver PL
    Semin Respir Crit Care Med; 2008 Apr; 29(2):211-9. PubMed ID: 18366002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Forum report: issues in the design of trials of drugs for the treatment of invasive aspergillosis.
    Bennett JE; Powers J; de Pauw B; Dismukes W; Galgiani J; Glauser M; Herbrecht R; Kauffman C; Lee J; Pappas P; Rex J; Verweij P; Viscoli C; Walsh T
    Clin Infect Dis; 2003 Apr; 36(Suppl 3):S113-6. PubMed ID: 12679894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.
    Maertens J; Theunissen K; Verhoef G; Verschakelen J; Lagrou K; Verbeken E; Wilmer A; Verhaegen J; Boogaerts M; Van Eldere J
    Clin Infect Dis; 2005 Nov; 41(9):1242-50. PubMed ID: 16206097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Forum report: issues in the evaluation of diagnostic tests, use of historical controls, and merits of the current multicenter collaborative groups.
    Bennett JE; Kauffman C; Walsh T; de Pauw B; Dismukes W; Galgiani J; Glauser M; Herbrecht R; Lee J; Pappas P; Powers J; Rex J; Verweij P; Viscoli C
    Clin Infect Dis; 2003 Apr; 36(Suppl 3):S123-7. PubMed ID: 12679896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized controlled trial assessing the efficacy of fluconazole in the treatment of pediatric tinea capitis.
    Foster KW; Friedlander SF; Panzer H; Ghannoum MA; Elewski BE
    J Am Acad Dermatol; 2005 Nov; 53(5):798-809. PubMed ID: 16243128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antifungal combination therapy: clinical potential.
    Baddley JW; Pappas PG
    Drugs; 2005; 65(11):1461-80. PubMed ID: 16033288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.
    Neofytos D; Horn D; Anaissie E; Steinbach W; Olyaei A; Fishman J; Pfaller M; Chang C; Webster K; Marr K
    Clin Infect Dis; 2009 Feb; 48(3):265-73. PubMed ID: 19115967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Issues in clinical trials of prophylaxis of fungal infections.
    Powers JH
    Clin Infect Dis; 2004 Oct; 39 Suppl 4():S211-7. PubMed ID: 15546120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antifungal therapy for febrile neutropenia: issues in clinical trial design.
    Marr KA
    Curr Opin Investig Drugs; 2004 Feb; 5(2):202-7. PubMed ID: 15043395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Counterpoint: alternative trial designs for antifungal drugs--time to talk.
    Powers JH
    Clin Infect Dis; 2001 Jul; 33(1):107-9. PubMed ID: 11389502
    [No Abstract]   [Full Text] [Related]  

  • 36. Antifungal therapy: lessons learned over the past 27 years.
    Dismukes WE
    Clin Infect Dis; 2006 May; 42(9):1289-96. PubMed ID: 16586389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination antifungal therapy.
    Patterson TF
    Pediatr Infect Dis J; 2003 Jun; 22(6):555-6. PubMed ID: 12799514
    [No Abstract]   [Full Text] [Related]  

  • 38. Status of combination therapy for refractory mycoses.
    Antoniadou A; Kontoyiannis DP
    Curr Opin Infect Dis; 2003 Dec; 16(6):539-45. PubMed ID: 14624103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses.
    Rex JH; Walsh TJ; Nettleman M; Anaissie EJ; Bennett JE; Bow EJ; Carillo-Munoz AJ; Chavanet P; Cloud GA; Denning DW; de Pauw BE; Edwards JE; Hiemenz JW; Kauffman CA; Lopez-Berestein G; Martino P; Sobel JD; Stevens DA; Sylvester R; Tollemar J; Viscoli C; Viviani MA; Wu T
    Clin Infect Dis; 2001 Jul; 33(1):95-106. PubMed ID: 11389501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of combination antifungal therapy in the treatment of invasive aspergillosis: a systematic review.
    Garbati MA; Alasmari FA; Al-Tannir MA; Tleyjeh IM
    Int J Infect Dis; 2012 Feb; 16(2):e76-81. PubMed ID: 22137271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.